Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026
Acute and Late Angiographic Lumen Assessment of the Coronary Artery Diameter After Drug Coated Balloon Angioplasty.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hande Şi̇şman Uzunoğlan Behice, Sezgin Uzunoğlan, Oğuzhan Abanoz, Esra Danişman, Mahsa Khanmohammadi, Nuray Kahraman A Y, Ahmet Bacaksiz, Nusret Açikgöz, Ramazan Özdemir, Mahmut Uluganyan
Аннотация
BACKGROUND: Drug-coated balloon (DCB) angioplasty has emerged as an alternative strategy. However, data on its mid-term angiographic and clinical outcomes remain limited.
METHODS: This study included 70 patients who underwent DCB angioplasty. Quantitative coronary angiography (QCA) measurements were obtained before, immediately after, and at follow-up angiography. The primary endpoint was binary restenosis (≥ 50% diameter stenosis), while secondary endpoints included late lumen loss (LLL), late lumen enlargement (LLE), and target lesion revascularization (TLR).
AIMS: We aimed to evaluate angiographic outcomes of DCB-treated de novo, in-stent restenosis (ISR), and chronic total occlusion (CTO) lesions using follow-up coronary angiography and quantitative coronary angiography (QCA), including acute lumen gain, late lumen loss, late lumen gain, and binary restenosis.
RESULTS: Among 70 patients, 25 (35.7%) developed binary restenosis at follow-up. Minimal lumen diameter, minimal lumen area, and percent diameter stenosis showed significant differences across pre-procedure, post-procedure, and follow-up assessments (all p < 0.001). LLL was observed in 72.9% of patients, whereas 27.1% exhibited LLE. Multivariate logistic regression identified active smoking as an independent predictor of binary restenosis (odds ratio [OR]: 9.23, p = 0.019), whereas female sex was associated with a lower risk (OR: 0.07, p = 0.031). No acute thrombosis occurred within 48 h, and one noncardiac death was reported during the first month.
CONCLUSION: DCB angioplasty demonstrated favorable mid-term angiographic efficacy with low rates of binary restenosis and TLR. These findings support DCB therapy as an effective revascularization strategy for selected patients with coronary artery disease.
METHODS: This study included 70 patients who underwent DCB angioplasty. Quantitative coronary angiography (QCA) measurements were obtained before, immediately after, and at follow-up angiography. The primary endpoint was binary restenosis (≥ 50% diameter stenosis), while secondary endpoints included late lumen loss (LLL), late lumen enlargement (LLE), and target lesion revascularization (TLR).
AIMS: We aimed to evaluate angiographic outcomes of DCB-treated de novo, in-stent restenosis (ISR), and chronic total occlusion (CTO) lesions using follow-up coronary angiography and quantitative coronary angiography (QCA), including acute lumen gain, late lumen loss, late lumen gain, and binary restenosis.
RESULTS: Among 70 patients, 25 (35.7%) developed binary restenosis at follow-up. Minimal lumen diameter, minimal lumen area, and percent diameter stenosis showed significant differences across pre-procedure, post-procedure, and follow-up assessments (all p < 0.001). LLL was observed in 72.9% of patients, whereas 27.1% exhibited LLE. Multivariate logistic regression identified active smoking as an independent predictor of binary restenosis (odds ratio [OR]: 9.23, p = 0.019), whereas female sex was associated with a lower risk (OR: 0.07, p = 0.031). No acute thrombosis occurred within 48 h, and one noncardiac death was reported during the first month.
CONCLUSION: DCB angioplasty demonstrated favorable mid-term angiographic efficacy with low rates of binary restenosis and TLR. These findings support DCB therapy as an effective revascularization strategy for selected patients with coronary artery disease.